UNSPSC 51144101: Amfecloral or amphecloral

This classification denotes a cns stimulant and anorexiant with the molecular formula C11H12Cl3N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6015XOA0BI, chemically known as 1-phenyl-n-(2,2,2-trichlorethyliden)-2-propylamin but more generally known as amfecloral, which bears US NIH Compound Identifier 21759. European Medicines Agency schedules Amfecloral in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05414MIG.

UNSPSC 51144101 Amfecloral or amphecloral is a Commodity code that, based on recent state and local solicitations, does not map to actual procurement activity under the code's nominal scope. The three recent opportunities posted under this code in 2026 solicit naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmacy benefit programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). None of these procurements align with amfecloral, a specific chemical compound. The mismatch between code assignment and actual sourcing needs suggests either a data-entry error in the state and local procurement system or that this UNSPSC code is not the appropriate taxonomic vehicle for the goods and services being bought.

The geographic footprint of recent activity spans Florida, Texas, and Minnesota, with the Minnesota cooperative vehicle extending to Oregon and other participating jurisdictions. Issuing bodies include county health departments (Seminole County), state health agencies (Texas HHS Commission), and state procurement offices administering cooperative purchasing programs (Minnesota Department of Administration). Representatives include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023, and the Minnesota MMCAP RFP for generic pharmaceuticals and OTC products to be awarded by May 15, 2026, through authorized wholesalers. The code shows little relevant recent activity aligned with its declared commodity name and warrants reclassification or clarification at the state and local level.